Market closed
Werewolf Therapeutics/$HOWL
Werewolf Therapeutics shares are trading lower after the company reported its Q1 2025 financial results.
9 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Werewolf Therapeutics
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
Ticker
$HOWL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
46
Website
HOWL Metrics
BasicAdvanced
$41M
-
-$1.63
0.38
-
Price and volume
Market cap
$41M
Beta
0.38
52-week high
$5.84
52-week low
$0.60
Average daily volume
274K
Financial strength
Current ratio
7.448
Quick ratio
7.312
Long term debt to equity
48.413
Total debt to equity
50.534
Interest coverage (TTM)
-15.81%
Management effectiveness
Return on assets (TTM)
-30.49%
Return on equity (TTM)
-76.33%
Valuation
Price to revenue (TTM)
21.172
Price to book
0.56
Price to tangible book (TTM)
0.56
Price to free cash flow (TTM)
-0.707
Growth
Revenue change (TTM)
-90.55%
Earnings per share change (TTM)
55.57%
3-year earnings per share growth (CAGR)
-46.95%
What the Analysts think about HOWL
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Werewolf Therapeutics stock.
HOWL Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
HOWL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
HOWL News
AllArticlesVideos
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewsWire·17 hours ago
Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
GlobeNewsWire·4 days ago
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewsWire·4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Werewolf Therapeutics stock?
Werewolf Therapeutics (HOWL) has a market cap of $41M as of May 09, 2025.
What is the P/E ratio for Werewolf Therapeutics stock?
The price to earnings (P/E) ratio for Werewolf Therapeutics (HOWL) stock is 0 as of May 09, 2025.
Does Werewolf Therapeutics stock pay dividends?
No, Werewolf Therapeutics (HOWL) stock does not pay dividends to its shareholders as of May 09, 2025.
When is the next Werewolf Therapeutics dividend payment date?
Werewolf Therapeutics (HOWL) stock does not pay dividends to its shareholders.
What is the beta indicator for Werewolf Therapeutics?
Werewolf Therapeutics (HOWL) has a beta rating of 0.38. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.